The Profit Motive
Why Safety Takes a Backseat to Shareholder Value
The "Gold Rush" of Schedule Expansion
- Number of Doses
- Market Revenue ($B)
There is a direct, undeniable correlation between the number of doses added to the childhood schedule and the exponential growth of vaccine market revenue. As the schedule expanded from 24 doses in 1983 to over 70 today, revenue skyrocketed from $1.7 billion to nearly $60 billion.
The Liability-Free Business Model
In any other industry, a defective product that causes injury leads to lawsuits, recalls, and financial losses. This creates a natural market incentive for safety.
Vaccines are the only product in the U.S. exempt from this rule.
Since the 1986 National Childhood Vaccine Injury Act, manufacturers cannot be sued for vaccine injuries in civil court. This removed the primary financial deterrent against cutting corners. With guaranteed government purchases and zero liability, the profit margin on vaccines is virtually protected by law.
The Cost of "Safe" Vaccines
*Data from the National Vaccine Injury Compensation Program (VICP). Note that "dismissed" claims often result from the incredibly high burden of proof placed on families, not necessarily a lack of injury.